(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's forecast annual revenue growth rate of 226.59% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Tonix Pharmaceuticals Holding's revenue in 2024 is $3,989,000.On average, 2 Wall Street analysts forecast TNXP's revenue for 2024 to be $430,480,605, with the lowest TNXP revenue forecast at $429,288,138, and the highest TNXP revenue forecast at $431,673,072. On average, 3 Wall Street analysts forecast TNXP's revenue for 2025 to be $559,648,636, with the lowest TNXP revenue forecast at $453,137,479, and the highest TNXP revenue forecast at $715,480,230.
In 2026, TNXP is forecast to generate $4,746,018,859 in revenue, with the lowest revenue forecast at $4,746,018,859 and the highest revenue forecast at $4,746,018,859.